Skip to Content
Uncategorized

Illegitimate Pharmaceutical Ads Prolific on Yahoo

The majority of the search engine’s drug ads are from rogue online pharmacies, according to researchers.

82% of drug ads on Yahoo lead to illegitimate Internet pharmacies, according to the second report from spam-monitoring group KnujOn and online pharmacy verifier LegitScripts. At the beginning of this month, these groups released a study suggesting that most of the pharmacy ads appearing on Bing lead users to fraudulent online pharmacies.

LegitScript/KnujOn

By searching Yahoo for terms like ‘generic Viagra’ or ‘pain meds,’ the researchers were able to order several prescription drugs without prescriptions (a violation of federal law) from various countries. The report lists details on 10 ads which led to these ‘rogue’ pharmacies.

In a press release issued today along with the second report, KnujOn founder Garth Bruen said,

“Like Bing, Yahoo! has been infiltrated by sophisticated illicit operations that are taking advantage of consumer need and gullibility.”

The group states that better online pharmacy verification systems are needed to minimize the sales of counterfeit drugs and addictive drugs without prescriptions.

Keep Reading

Most Popular

The inside story of how ChatGPT was built from the people who made it

Exclusive conversations that take us behind the scenes of a cultural phenomenon.

Sam Altman invested $180 million into a company trying to delay death

Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.

ChatGPT is about to revolutionize the economy. We need to decide what that looks like.

New large language models will transform many jobs. Whether they will lead to widespread prosperity or not is up to us.

GPT-4 is bigger and better than ChatGPT—but OpenAI won’t say why

We got a first look at the much-anticipated big new language model from OpenAI. But this time how it works is even more deeply under wraps.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.